SUBSCRIBE
SUBSCRIBE
News   Drug Development

MediGene, Inc. Drug Extends Pancreatic Cancer Survival

September 16, 2008 | 
1 min read

LONDON, Sept 16 (Reuters) - Patients with inoperable pancreatic cancer live substantially longer when given MediGene’s experimental drug EndoTAG-1 on top of standard chemotherapy, according to clinical trial results.

Clinical research Phase II Europe
MORE ON THIS TOPIC
Sanofi's Distribution Center in Quebec, Canada
Multiple sclerosis
Sanofi, Denali Abandon Mid-Stage Multiple Sclerosis Study on Disappointing Data
October 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Drug Development
How AI Could Ease Tension in Clinical Trials
October 10, 2024
 · 
1 min read
 · 
Lori Ellis
Sign in front of Pfizer in Quebec, Canada
Prostate cancer
Pfizer Phase III Prostate Cancer Win Builds Case for Broader Label for Talzenna-Xtandi Combo
October 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Concept art of a gene therapy showing a syringe injecting into a 3D DNA helix
Gene therapy
7 Children Receiving Bluebird’s Gene Therapy Developed Blood Cancers: Study
October 10, 2024
 · 
2 min read
 · 
Tristan Manalac